Biogen (BIIB) Reports New Data Showing Three Years of Continuous Treatment with Dual-Acting LEQEMBI Continues to Significantly Benefit Early Alzheimer's Disease Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. IBM
3. PRIM
4. MU
5. DPZ
6. NAVN
7. DFTX
8. META
9. IMNN
10. ACN

Go back to Biogen (BIIB) Reports New Data Showing Three Years of Continuous Treatment with Dual-Acting LEQEMBI Continues to Significantly Benefit Early Alzheimer's Disease Patients

Biogen (BIIB) tops Q2 expectations, raises profit guidance

August 1, 2024 7:27 AM EDT

Biogen (NASDAQ: BIIB) reported its second-quarter results on Thursday, surpassing analyst expectations with an adjusted EPS of $5.28, significantly higher than the estimated $4.01.

The company's revenue also exceeded forecasts, coming in at $2.47 billion against a consensus estimate of $2.39 billion. Despite a flat year-over-year (YoY) total revenue, the adjusted EPS saw a notable 31% increase YoY.

The pharmaceutical giant's strong performance is reflected in its raised full-year... More